Gastroenterology

Experts in hepatology discuss the pathophysiology of HE and how certain factors influence the brain in HE.

The treatment is the second live microbiota therapeutic approved by the FDA, coming just a few months after the agency approved RBX2660 for recurrent C. difficile infections.

Dr James Williams shares insight on factors leading to delays in hepatic encephalopathy (HE) diagnosis, the importance of early detection, and strategies to improve diagnosis in the in-patient setting.

An expert in emergency medicine outlines his approach to the clinical evaluation of hepatic encephalopathy.

The results also show 10.3% of the patients with celiac disease that was histopathological confirmed were seronegative to Anti-TtG-IgA, but seropositive to anti-DGP-IgA and/or Anti-DGP-IgG.

Dr Paul Feuerstadt joins Dr David Hudesmand and Dr Jordan Axelrad in a discussion about treatment approaches for C difficile infections, and the latest advances in treating recurrent infections with fecal microbiota transplantation.

In addition, 17 female patients who completed PENFS showed improvements in various symptoms, such as pain, disability, and catastrophizing, while carbohydrate degradation and LCFA synthesis pathways decreased in the post-treatment and follow-up analysis.

There were significant positive associations found of overweight, obesity, and a 5-unit increase in BMI with colorectal cancer risk when using BMI measured 8-10 years prior to diagnosis.

National data show mortality rates climbed 23% in 2020, primarily driven by increases among American Indian or Alaska Native people.

Patients in long-remission also presented with fecal bacterial composition that was similar to what was found in the healthy control group and there was a positive correlation between Akkermansia muciniphila abundance and time in remission.

Disease activity and treatment with a small-molecule or an investigation drug were independently linked to an exclusion diet, while a history of stenosis and active disease were associated with fasting.

Kimberly A. Brown, MD, reviews classifying the severity of HE and defines covert vs overt HE.

Arun B. Jesudian, MD, and Kimberly A. Brown, MD, provide an overview of hepatic encephalopathy, signs and symptoms, and underlying liver disease as a major risk factor.

Drs Arun Jesudian and James Williams share thoughts on patients with hepatic encephalopathy who are at risk of hospitalization, poorer patient and economic outcomes associated with readmission rates, and the impact of hepatic encephalopathy on quality of life.

James Williams, MS, DO, FACEP, describes the presentation of hepatic encephalopathy (HE) in patients and challenges associated with diagnosis.

The results show 52.5% of patients achieved clinical remission at week 96, while 59.0% saw endoscopic improvement, 35.9% achieved endoscopic remission, and 70.5% achieved a clinical response.

There are many reasons why biosimilars are not utilized in gastroenterology, mainly patients present younger and treatments can lose efficacy over time.

Some traditional sarcopenia assessment techniques included direct measurements on cross sectional imaging, but cross sectional imaging also comes with increased time, cost, and radiation exposure.

The rate of CDI recurrence through week 9 using the efficacy analysis 3 definition was 13.8% for the high-dose VE303 group, compared to 37% for the low-dose VE303 group and 45.5% for the placebo group.

Using the bidirectional Montreal classification system, which accounts for disease regression, showed that 90% of patients exhibited inflammatory disease behavior at 5 years, compared to 58% if the hierarchical, unidirectional Montreal classification system was implemented.

The FDA cited manufacturing concerns in their letter for the potential ulcerative colitis treatment.

April is Donate Life Month, where many advocate for more living organ donors.

Of the patients in the first cohort, 0.7% had HBV, all of which had a history of drug use. In addition, 3% were anti-HCV positive, 8 of which had a history of drug.

Metabolic dysfunction was associated with increased risk of HCC, while patients with only metabolic dysfunction had the highest risk because the sustained virological response achievement.

The cumulative probabilities of treatment initiation after meeting the criteria was not significantly different between the different racial groups and the incidence of major adverse liver outcomes was 0.1 per 100 person-years and did not differ by race.